Loading...
•
Jun 30, 2022
Inotiv Q3 2022 Earnings Report
Inotiv's Q3 2022 financial results were announced, showing revenue growth driven by DSA and RMS segments.
Key Takeaways
Inotiv reported record revenues, Adjusted EBITDA, and backlog in Q3 2022, driven by organic growth, acquisitions, and favorable pricing. The company continued to expand its portfolio of services and progress its capacity expansion initiatives.
Revenue increased due to a rise in DSA revenue and incremental RMS revenue.
Gross profit increased due to higher DSA and RMS gross profit.
Operating expenses increased due to acquisitions and strategic investments.
Continued investing in internal capabilities to provide additional service offerings such as laboratory solutions, pathology services, biotherapeutics and genetic toxicology.
Inotiv
Inotiv
Inotiv Revenue by Segment
Revenue by Segment
RMS Revenue
CapyFin.comDSA Revenue
CapyFin.comRevenue & Expenses
Visualization of income flow from segment revenue to net income